245 related articles for article (PubMed ID: 22252001)
1. Correlates of vaccine protection from influenza and its complications.
McCullers JA; Huber VC
Hum Vaccin Immunother; 2012 Jan; 8(1):34-44. PubMed ID: 22252001
[TBL] [Abstract][Full Text] [Related]
2. Are we ready for universal influenza vaccination in paediatrics?
Principi N; Esposito S
Lancet Infect Dis; 2004 Feb; 4(2):75-83. PubMed ID: 14871631
[TBL] [Abstract][Full Text] [Related]
3. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
4. HI responses induced by seasonal influenza vaccination are associated with clinical protection and with seroprotection against non-homologous strains.
Luytjes W; Enouf V; Schipper M; Gijzen K; Liu WM; van der Lubben M; Meijer A; van der Werf S; Soethout EC
Vaccine; 2012 Jul; 30(35):5262-9. PubMed ID: 22691431
[TBL] [Abstract][Full Text] [Related]
5. Low seroprotection against preseasonal influenza local strains in children might predict the upcoming epidemic influenza strains.
Su WJ; Shao PL; Liu MT; Liu DP; Huang KC; Chang LY; Lu CY; Wang JR; Shih SR; Huang DT; Chi H; Huang LM
Clin Infect Dis; 2010 Jul; 51(2):171-6. PubMed ID: 20528478
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
[TBL] [Abstract][Full Text] [Related]
7. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
[TBL] [Abstract][Full Text] [Related]
8. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM
Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967
[TBL] [Abstract][Full Text] [Related]
9. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.
Treanor JJ; El Sahly H; King J; Graham I; Izikson R; Kohberger R; Patriarca P; Cox M
Vaccine; 2011 Oct; 29(44):7733-9. PubMed ID: 21835220
[TBL] [Abstract][Full Text] [Related]
10. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and protective efficacy of influenza vaccination.
Hannoun C; Megas F; Piercy J
Virus Res; 2004 Jul; 103(1-2):133-8. PubMed ID: 15163501
[No Abstract] [Full Text] [Related]
12. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.
Roman F; Vaman T; Kafeja F; Hanon E; Van Damme P
Clin Infect Dis; 2010 Sep; 51(6):668-77. PubMed ID: 20687838
[TBL] [Abstract][Full Text] [Related]
13. Age-dependent prevalence of antibodies cross-reactive to the influenza A(H3N2) variant virus in sera collected in Norway in 2011.
Waalen K; Kilander A; Dudman SG; Ramos-Ocao R; Hungnes O
Euro Surveill; 2012 May; 17(19):. PubMed ID: 22607964
[TBL] [Abstract][Full Text] [Related]
14. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
[TBL] [Abstract][Full Text] [Related]
15. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children.
Black S; Nicolay U; Vesikari T; Knuf M; Del Giudice G; Della Cioppa G; Tsai T; Clemens R; Rappuoli R
Pediatr Infect Dis J; 2011 Dec; 30(12):1081-5. PubMed ID: 21983214
[TBL] [Abstract][Full Text] [Related]
16. Adjuvanted or whole-virion vaccine for 2009 influenza A (H1N1).
Barrett PN; Ehrlich HJ
Lancet Infect Dis; 2011 Jul; 11(7):496-7; author reply 497-8. PubMed ID: 21700237
[No Abstract] [Full Text] [Related]
17. [Influenza vaccination? An extra vaccine for seniors?].
MMW Fortschr Med; 2003 Sep; 145(37):61. PubMed ID: 14584449
[No Abstract] [Full Text] [Related]
18. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
[TBL] [Abstract][Full Text] [Related]
20. Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations.
Burt D; Mallett C; Plante M; Zimmermann J; Torossian K; Fries L
Expert Rev Vaccines; 2011 Mar; 10(3):365-75. PubMed ID: 21434804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
